#Obesity medicine
Chronic weight management as a clinical specialty.
Semaglutide CV edge over tirzepatide
A 47-trial meta-analysis finds semaglutide cuts MACE by 29% and CV death by 19%. Tirzepatide trends protective but lacks the trial base to confirm it.
Weight-loss drugs and fertility: the data
A meta-analysis of seven trials finds orlistat and semaglutide may boost ovulation and pregnancy rates in women with obesity.
ACP review: which obesity drugs pay off?
A new ACP systematic review rates tirzepatide high-value but flags poor study quality across all obesity drug cost models.
ACP: tirzepatide, semaglutide first-line
A living ACP guideline published 16 June 2026 places tirzepatide and semaglutide first among pharmacologic obesity treatments for US outpatient adults.
GLP-1 drugs and plastic surgery risks
A 2026 review examines wound risks, aspiration concerns and body-contouring challenges when aesthetic surgery patients use GLP-1 agonists.
Medicare's $50 GLP-1 bridge may never end
A temporary Medicare program offers GLP-1 weight-loss drugs for $50 a month from July 2026. It has already been extended once.
Semaglutide QoL gains: real but modest
A 2026 meta-analysis finds semaglutide 2.4 mg improves physical functioning scores, but gains fall below clinically meaningful thresholds.
Oral Wegovy tracker: FDA, EMA, MHRA
The FDA, EMA, and MHRA have now all approved oral Wegovy for weight management. Here is the regulatory timeline and how the three decisions compare.
Wegovy weight loss pill gets UK approval
The MHRA approved oral Wegovy (semaglutide 25 mg tablets) for weight management in adults on 11 June 2026, making it the first oral GLP-1 for obesity in the UK.
Do GLP-1 drugs reduce fat graft survival?
A scoping review flags several mechanisms through which GLP-1 receptor agonists may reduce fat graft survival. No clinical data exist yet.
Semaglutide at 6 months: STEP trial data
Community posts report 80-90 lbs lost in six months on semaglutide. Here is what STEP trial data shows about timelines and plateaus.
Semaglutide weight loss: the trial data
STEP 5 shows 15% average weight loss sustained at two years. What the data says about body composition, eating behaviour, and stopping.